All Eyes Galmed Pharmaceuticals (Nasdaq: GLMD) As It Reaches $2.90 Marking An Approx. 66% Move

Market Crux Exclusive Profile For Monday 3/17/2025 Has Been Announced!  Galmed Pharmaceuticals (Nasdaq: GLMD) Is Our Next Potential Breakout  Idea For Tomorrow—Here’s Why… According To Technical Indicators, (GLMD) Appears To Be Entering An Oversold Territory — Which Could Suggest The Potential For A Trend Reversal. There’s Less Than 1.65M Shares Listed In The Public Float For (GLMD) — Which Could Lead To The Potential For Significant Swings If Demand Begins To Shift. Then—Just A Few Days Ago, On Friday 3/14/2025, Maxim Group Published A Report With A $12 Target On (GLMD) — Which Suggests An Upside Potential Of  Over 597% From Its $1.72 Close. Keep Reading To See Why Galmed Pharmaceuticals (NASDAQ: GLMD) Is Topping Our Watchlist For Early This Morning… March 17, 2025 Dear Reader, We have all eyes on Galmed Pharmaceuticals (NASDAQ: GLMD) right now. Shortly after the bell, (GLMD) reached $2.90, marking an approximate 66% move from Friday’s $1.74 close. Please tell me you pulled this up already. Keep reading to see why (GLMD) is topping our watchlist early this morning. If history is any indication, this could be worth watching.  Here’s why… The last time we covered (GLMD), it skyrocketed approximately 182% in less than 24 hours. And with our previous two Sunday Night Profiles combining for 175% (approx.) moves, we’re keeping a close eye on (GLMD) heading into tomorrow morning’s session. You see, biotech and pharma are some of the most exciting industries, where a single breakthrough can turn an under-the-radar company into a major market player overnight. Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on liver, metabolic, and fibro-inflammatory diseases.  The company is advancing Aramchol Meglumine, a potential treatment for Primary Sclerosing Cholangitis (PSC) and other fibrotic conditions.  Aramchol, in Phase 3 clinical development, has already demonstrated significant fibrosis improvement in patients with NASH and fibrosis, as published in Hepatology.  As the most advanced SCD-1 downregulator in clinical trials, Aramchol continues to show potential in multiple therapeutic areas. Learn more here. On Friday, 3/14/2025, Maxim Group published a report which listed Galmed Pharmaceuticals (Nasdaq: GLMD) with a $12 target, which suggests an upside potential of over 597% from its $1.72 close. Galmed Pharmaceuticals (Nasdaq: GLMD) Is Topping Our Early Watchlist This Morning—And Here’s Why… 1. Technical Signals: According to technical indicators found on Barchart, (GLMD) appears to be entering an oversold territory, which could suggest the potential for a trend reversal. 2. Razor Float: There’s less than 1.65M shares listed in the public float for (GLMD). This limited float could lead to the potential for significant swings if demand begins to shift. 3. Recent Analyst Coverage: Just a few days, on Friday 3/14/2025, Maxim Group published a report with a $12 target on (GLMD), which suggests an upside potential of over 597% from its $1.72 close. Now’s The Time to Consider Adding Galmed Pharmaceuticals (Nasdaq: GLMD) to Your Radar This Morning—While It’s Still Early… We’ve seen it before—when a profile like this starts catching momentum, things can move fast. Consider taking a look at (GLMD) while it’s still early. (GLMD) is at the top of our watchlist early this morning. We have all eyes on Galmed Pharmaceuticals (NASDAQ: GLMD) right now. Shortly after the bell, (GLMD) reached $2.90, marking an approximate 66% move from Friday’s $1.74 close. Now remember— the last time we covered (GLMD), it moved approximately 182% in less than 24 hours.  And please keep an out for my next update—it could be out to you any minute. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Headline Media LLC has not been compensated for the March 16th and 17th, 2025's profile on (GLMD:US). Neither Headline Media LLC, TD Media LLC and their members own shares of (GLMD:US).

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice